Literature DB >> 31280914

Thyrotoxicosis-induced cardiomyopathy treated with venoarterial extracorporeal membrane oxygenation.

Ivo Genev1, Michelle D Lundholm1, Mary Ann Emanuele2, Edwin McGee3, Verghese Mathew4.   

Abstract

A 37-year-old woman with no past medical history presented with longstanding untreated hyperthyroidism and consequentially developed thyrotoxicosis-induced cardiomyopathy. Upon admission, she was noted with a heart rate of 172 beats per minute and an EKG consistent with supraventricular tachycardia which was unresponsive to adenosine. Shortly after the initiation of a non-cardioselective beta-blocker for the treatment of persistent tachycardia, she developed profound cardiogenic shock refractory to vasopressors and inotropes. She was diagnosed with thyroid storm, which was ultimately attributed to Graves' Disease and controlled with propylthiouracil, potassium iodide drops, and hydrocortisone. Extracorporeal membrane oxygenation (ECMO) was successfully used as a temporizing measure while her thyroid hormone level normalized and cardiac function recovered. Patients with longstanding untreated hyperthyroidism may be dependent on the induced hyperadrenergic state to compensate for low-output cardiac failure, therefore it is important to exercise caution when initiating beta-adrenergic blockade. Given the expected disease time-course in cases of acute decompensation, ECMO remains a viable option for short-term mechanical circulatory support.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiomyopathy; Extracorporeal membrane oxygenation; Graves’ disease; Hyperthyroidism

Year:  2019        PMID: 31280914     DOI: 10.1016/j.hrtlng.2019.06.006

Source DB:  PubMed          Journal:  Heart Lung        ISSN: 0147-9563            Impact factor:   2.210


  1 in total

Review 1.  Crash Landing of Thyroid Storm: A Case Report and Review of the Role of Extra-Corporeal Systems.

Authors:  Shir Lynn Lim; Kangjie Wang; Pak Ling Lui; Kollengode Ramanathan; Samantha Peiling Yang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-20       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.